Full name
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus
NCT Number
NCT06411249
Geography
US
Non-US
Locations
Argentina, Brazil, France, Germany, Greece, Italy, Japan, Mexico, Portugal, Spain, United States
Primary Endpoints
- Part A: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52
External Link
https://clinicaltrials.gov/study/NCT06411249
Order
0
Disease
Version
Phase
4